TLT appoints Dr Art Tucker as Clinical Director

1 June 2012. Welwyn Garden City, UK. Tarilian Laser Technologies is proud to announce the appointment of a leading expert from the William Harvey Institute, Dr Art T. Tucker, as New Clinical Director of TLT.

Dr Tucker is a Principal Clinical Scientist and Vascular Researcher at St Bartholomew’s Hospital, London; Honorary Reader at The William Harvey Research Institute, Queen Mary University of London; Chairman, NRES Committee London - City & East, a National Research Ethics Advisor, National Patients Safety Agency, and a member of EUCROF.

Commenting on his appointment, Dr Tucker said that, “I am excited to join TLT, as this dynamic and world-class company now consolidates it’s unique and prominent position in the world of blood pressure measurement and haemodynamics.

"TLT has pioneered a very powerful technology and finessed its applications not just in blood pressure anywhere in the body including the eye, but also in other equally exciting and important areas of medicine including foetal monitoring, peripheral vascular disease and others that we will announce in due course. TLT continues to excite the medical community with it’s very promising entry and I am excited to take part in this journey with TLT that will redefine the state of the art of Medicine.”

Dr Sandeep Shah, CEO of Tarilian Laser Technologies, said that, “Everyone here at TLT is thrilled that Dr Tucker has agreed to join our management team as we now accelerate the development of what will become a unique sensor company.

"He will enhance our team as Dr Tucker brings unique skills in international clinical trial design, execution and governance together with globally renowned operational and execution expertise through his roles at QMUL, The William Harvey Institute and Seahorse Scientific Services. He will into the future dynamise our international team considerably and lead on the TLT clinical programme strategy and execution across our global projects.”


1. Dr Art Tucker
— introduction to TLT

2. Dr Tucker outlines TLT's future clinical programmes

3. Dr Tucker comments on the clinical trial of the TLT blood pressure sensor.

4. Dr Tucker describes the utility and applications of the TLT sensor.

5. Dr Tucker comments on TLT's optical pressure modulation technology

6. Dr Tucker outlines the problem of hypertension


- ends -

About Tarilian Laser Technologies
Tarilian Laser Technologies (TLT) was established in 2006 by Dr Sandeep Shah, CEO, and Nita Shah, Programme Director, to further develop optical technology that they had discovered could measure blood pressure in a unique way. Following completion of the research programme the company filed a series of patents and set up an international R&D team to progress with the development of the sensor technology. TLT has already successfully completed its international FDA and MHRA pivotal regulatory clinical trial, working with global experts in clinical medicine and clinical trials, including from Barts Hospital, London and the William Harvey Institute, London. TLT is now completing the development and entering the manufacturing translation and scale-up programme for its highly innovative consumer blood pressure device that is a stand-alone cuff-less device and has unique features including superior accuracy and ease of use. TLT is expecting first year sales revenue of its TLT Sapphire innovative device to reach over 1 million units. Tarilian Laser Technologies is headquartered in Welwyn Garden City, Hertfordshire, UK.


Dr Sandeep Shah, CEO, Tarilian Laser Technologies. Tel: +44 (0) 1707 356 112

For further press information, please contact:
Harry Wood
Tel : +44 (0)1252 691 590
Medical Technology Business Europe, 29 Pinewood Park, Farnborough, Hampshire, UK